Patents Represented by Attorney, Agent or Law Firm David P. Lentini
-
Patent number: 8227459Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: GrantFiled: April 3, 2008Date of Patent: July 24, 2012Assignee: Prosetta Antiviral Inc.Inventors: Jacob Plattner, Colm Kelleher, Vishwanath Lingappa, Beverly Freeman, William Hansen
-
Patent number: 8212677Abstract: Systems, apparatuses, and methods for tracking the status and use of packaged goods are provided. The systems of the invention coordinate various stakeholders, hardware devices, computer software systems, standards, methods, procedures, practices and their interconnection in ways that lead to greater efficiency, safety, and efficacy, along with potentially lower cost, and less waste in the delivery of packaged goods and their use. In one aspect a Medication Management System (“MMS”) that tracks the status of packaged medications and patient compliance is also provided.Type: GrantFiled: February 12, 2008Date of Patent: July 3, 2012Inventor: Alexander Ferguson
-
Patent number: 8140062Abstract: Methods and apparatus, including computer program products, for surreptitiously installing, monitoring, and operating software on a remote computer controlled wireless communication device are described. One aspect includes a control system for communicating programming instructions and exchanging data with the remote computer controlled wireless communication device.Type: GrantFiled: September 12, 2008Date of Patent: March 20, 2012Assignee: Oceans' Edge, Inc.Inventors: Steven T. Hildner, Thomas P. Shanley, Tom Krussel, Paul Neuner, Robert Adam McKay, Jay Lukin, Sam Emara, Nathan Klonoski
-
Patent number: 8131281Abstract: Methods and apparatus, including computer program products, for surreptitiously installing, monitoring, and operating software on a remote computer controlled wireless communication device are described. One aspect includes a control system for communicating programming instructions and exchanging data with the remote computer controlled wireless communication device.Type: GrantFiled: September 12, 2008Date of Patent: March 6, 2012Assignee: Oceans' Edge, Inc.Inventors: Steven Hildner, Thomas Shanley, Tom Krussel, Paul Neuner, Robert Adam McKay, Jay Lukin, Sam Emara, Nathan Klonoski
-
Patent number: 8080528Abstract: Compositions and methods for preventing and treating wasting disorders, such as cachexia and anorexia, are provided. In one aspect, the present invention provides a method for preventing and treating a wasting disorder in a mammal. In one embodiment, the method of the invention comprises administering to such mammal a macrolide and a ?2-adrenergic agonist in combination such that the macrolide and said ?2-agonist are administered in amounts effective to prevent or at least alleviate said wasting disorder.Type: GrantFiled: December 20, 2006Date of Patent: December 20, 2011Assignee: The Releef InitiativeInventors: Richard Kenley, Jonas Ekblom, Mikhail Denissenko
-
Patent number: 6670389Abstract: Laulimalide compounds, intermediates thereto and methods for their preparation, and methods for their use in the treatment of diseases characterized by cellular hyperproliferation.Type: GrantFiled: February 8, 2002Date of Patent: December 30, 2003Assignee: Kosan Biosciences, Inc.Inventors: Gary Ashley, Brian Metcalf
-
Patent number: 6660862Abstract: Polyketide compounds of the formula but not including FK-506, FK-520, 18-hydroxy-FK520 and 18-hydroxy-FK-506.Type: GrantFiled: April 3, 2001Date of Patent: December 9, 2003Assignee: Kosan Biosciences, Inc.Inventors: Christopher Reeves, Daniel Chu, Chaitan Khosla, Daniel Santi, Kai Wu
-
Patent number: 6593302Abstract: Compounds of the formula wherein Ra is H; substituted or unsubstituted alkyl (1-10C); substituted or unsubstituted alkenyl (2-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); or ORa is replaced by H; Rb is H or halogen; Rc is H or a protecting group; Rd is methyl, unsubstituted alkyl (3-10C); substituted alkyl (1-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); substituted or unsubstituted arylalkenyl (5-20C); substituted or unsubstituted arylalkynyl (5-20C); substituted or unsubstituted amidoarylalkyl (5-20C); substituted or unsubstituted amidoarylalkenyl (5-20C); or substituted or unsubstituted amidoarylalkynyl (5-20C); Re is H or a protecting group; L is methylene or carbonyl; T is —O—, —N(R)—, —N(OR)—, —N(NHCOR)—, —N(N═CHR)—, or &mdType: GrantFiled: February 13, 2002Date of Patent: July 15, 2003Assignee: Kosan Biosciences, Inc.Inventors: Daniel Chu, Gary Ashley
-
Patent number: 6569867Abstract: The present invention relates to novel polyketides, host cells that produce the novel compounds, and methods fort their use. The compounds of the present invention are cyclic polyketides (also referred to as a “macrolides” or “macrolactones”) that include as part of their structure and bind to a FK binding protein wherein R4 and R5 are each selected from the group consisting of hydrogen, methyl, ethyl, and methoxy, provided that at least one of R4 and R5 is hydrogen, methyl, or ethyl. As will be explained in greater detail below, the compounds of the present invention have properties such as favorable P450 enzyme activity profiles that are desirable for use of these compounds as drugs.Type: GrantFiled: May 10, 2001Date of Patent: May 27, 2003Assignee: Kosan Biosciences, Inc.Inventors: Daniel Chu, Maria Fardis, Chaitan Khosla, Christopher Reeves, Daniel Santi, Andreas Schirmer
-
Patent number: 6562795Abstract: The present invention provides novel macrolide compounds of the formulas wherein: R is hydroxyl or methoxy; R1 is selected from the group consisting of hydrogen, hydroxyl, halide, NH2, OR9, where R9 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl or heteroaryl and R10 and R11 are each independently hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, or aryl; R2 and R3 are each independently selected from the group consisting of hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, alkylaryl, alkenylaryl, alkynylaryl or R2 and R3 together form a cycloalkyl or a cycloaryl moiety; R4 is hydrogen or methyl; R5 is hydrogen, hydroxyl, oxo, or together with R6 and the carbons to which they are attached form a cyclic carbonate; R6 is hydrogen, hydroxyl, OR12 where R12 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, or together with R5 and the carbons to which they are attached form a cyclic carbonate; R7 is methyl, C3-C10 alkyl, C2-C10 alkenyl, C2-C1Type: GrantFiled: February 15, 2001Date of Patent: May 13, 2003Assignee: Kosan Biosciences, Inc.Inventors: Gary Ashley, Mark Burlingame, Christopher Carreras, Daniel Santi
-
Patent number: 6514944Abstract: The invention is directed towards antibacterial compounds. The invention concerns macrolide antibiotics useful as antiinfective agents.Type: GrantFiled: December 27, 2000Date of Patent: February 4, 2003Assignee: KOSAN Biosciences, Inc.Inventor: Daniel T. W. Chu
-
Patent number: 6489344Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: GrantFiled: June 18, 1999Date of Patent: December 3, 2002Assignee: Chiron CorporationInventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
-
Patent number: 6423685Abstract: A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human “uPA” or “hUPA”) or a fragment or derivative thereof. Pharmaceutical compositions containing such molecules and methods of using them to treat uPA-mediated and uPA receptor-mediated disorders are also provided.Type: GrantFiled: March 5, 1999Date of Patent: July 23, 2002Assignee: Chiron CorporationInventors: Robert J. Drummond, Steve Rosenberg
-
Patent number: 6417185Abstract: Novel pyridine and pyrimidine derivatives which selectively inhibit glycogen synthase kinase 3 are provided and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions which may be mediated by glycogen synthase kinase 3.Type: GrantFiled: June 18, 1999Date of Patent: July 9, 2002Assignee: Chiron CorporationInventors: Dane A. Goff, Stephen D. Harrison, John M. Nuss, David B. Ring, Xiaohui A. Zhou
-
Patent number: 6387920Abstract: Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: April 11, 2001Date of Patent: May 14, 2002Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Jennifer C. Moore, Beata Krywult, Thayalan Navaratnam, Rajinder Singh, Rob Trainor, Liang Wang
-
Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
Patent number: 6387886Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.Type: GrantFiled: November 28, 2001Date of Patent: May 14, 2002Assignee: Chiron CorporationInventors: Alan B. Montgomery, William R. Baker -
Patent number: 6361962Abstract: Methods, materials, and systems for detecting toxins are provided. In one aspect, a toxin contamination detector includes a substrate on which a bar code is printed. The bar code has a first color (e.g., black) that is effective to reflect light from a bar code scanning device to produce a bar code result. A toxin indicator is also included. The toxin indicator has a second color in the absence of toxin, which second color does not substantially affect or alter the bar code result. However, the toxin indicator presents a third color in the presence of toxin which substantially changes the bar code result; thereby indicating the presence of toxin.Type: GrantFiled: October 6, 1999Date of Patent: March 26, 2002Assignee: Verseau GroupInventors: David P. Lentini, Vincent S. Camacho
-
Patent number: 6291505Abstract: Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: August 6, 1999Date of Patent: September 18, 2001Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Beata Krywult, Rajinder Singh, Liang Wang
-
Patent number: 6268341Abstract: Unfucosylated huPAR polypeptides that contains huPA1-48 (SEQ ID NQ:22) are provided. These polypeptides are useful for treating diseases wherein antagonism of huPAR is therapeutically beneficial.Type: GrantFiled: December 23, 1998Date of Patent: July 31, 2001Assignee: Chiron CorporationInventors: Steven Rosenberg, Jennifer R. Stratton-Thomas
-
Patent number: RE43435Abstract: A financial instrument, exchange, and method based upon the volatility in the price of an underlying. Such volatility contracts have a creation date, a term expiring at an expiration date, and a settlement price at the expiration date defined as “Svol”, under the formula: Svol=f{Rt1,Rt2,Rt3, . . . , Rtn}, wherein: Svol?0, n>1, t=each of a series of observation points from 1 to “n”; Rt=return of the underlying based upon each of the observation points in time “tn”; and n=total number of observations within the term. The term is selected from the group consisting of days, months, quarters and years. The settlement price is annualized based upon an approximate total number of periods in a calendar year. Rt is selected from the group consisting of: R t = ln ? ( M t M t - 1 ) ? ? and ? ? R t = ( M t - M t - 1 M t - 1 ) wherein: Mt=mark-to-market price at time “t”; and Mt?1=mark-to-market price at the time immediately prior to time “t”, at time “t?1”.Type: GrantFiled: March 16, 2010Date of Patent: May 29, 2012Assignee: Volatility Partners, LLCInventor: Robert P. Krause